Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab for Chronic Rhinosinusitis with Nasal Polyps/Eosinophilic Chronic Rhinosinusitis
CTR20210606Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of mepolizumab in chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic chronic rhinosinusitis (ECRS), sponsored by GSK. Started Apr 2021; status: completed.
02
Drugs
mepolizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)eosinophilic chronic rhinosinusitis (ECRS)
Beyond the preview
Go deeper on CTR20210606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210606.